Andy Bosyi
Feb 18, 2014
Novartis Criticizes India Patent Landscape
Looks like Novartis is joining in on the controversy surrounding the Global IP Center's IP Ranking Report with regards to India's treatment of pharmaceutical patents.
Looks like Novartis is joining in on the controversy surrounding the Global IP Center's IP Ranking Report with regards to India's treatment of pharmaceutical patents.